KSQ

17 articles about KSQ

• KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

  11/29/2023

  KSQ Therapeutics, Inc. in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), today announced the Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase 1/2 clinical study of KSQ-001EX.

• KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer

  7/13/2023

  KSQ Therapeutics, Inc. announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279.

• KSQ Appoints Mahesh Karande to its Board of Directors

  12/8/2022

  KSQ Therapeutics today announced the appointment of Mahesh Karande, President and CEO of Omega Therapeutics, to the company's board of directors.

• KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, a First-In-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

  12/7/2022

  KSQ Therapeutics today announced the initiation of dosing in the combination therapy portion of Study KSQ-4279-1101, a Phase 1 clinical study of KSQ-4279 in patients with advanced solid tumors.

• KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/22/2021

  KSQ Therapeutics today announced that Qasim Rizvi, Chief Executive Officer of KSQ, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 4:40 PM (ET).

• KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

  9/14/2021

  KSQ Therapeutics today announced the initiation of dosing in a Phase 1 clinical study of KSQ-4279, a first-in-class USP1 inhibitor, in patients with advanced solid tumors.

• KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer

  5/13/2021

  KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics ® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer.

• KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer

  1/25/2021

  KSQ ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer

• 

  KSQ Therapeutics Identifies New Target for Refractory Solid Tumors

  2/10/2020

  KSQ announced it had identified and validated a novel target, CT-1, that it plans to develop an engineered tumor-infiltrating lymphocyte (eTIL) therapy for.
• 

  BioSpace Movers and Shakers: April 19

  4/19/2019

  Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.

• KSQ Therapeutics Announces Appointment of Douglas Pagán as Chief Financial Officer

  4/16/2019

  KSQ Therapeutics announced the appointment of Douglas Pagán as Chief Financial Officer.

• KSQ Therapeutics Announces Appointment of Beni B. Wolf, MD, PhD, as Chief Medical Officer

  4/16/2019

  KSQ Therapeutics announced the appointment of Beni B. Wolf, MD, PhD, as Chief Medical Officer.

• 

  Artificial Intelligence Is the Next Big Player in Genomics

  12/11/2018

  According to consultant firm Frost & Sullivan, artificial intelligence (AI) systems will be the next big players in both global healthcare and individual gene editing. By 2021, the firm predicts that AI will be responsible for 6.7 billion dollars in revenue.

• KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD-1 Resistant Solid Tumors

  9/28/2018

  Company’s Pipeline Spans Three Oncology Drug Categories: Adoptive T-Cell Therapies, Immuno-Oncology Monotherapies and Targeted Therapies

• 

  KSQ Gains $80 Million Series C Financing for CRISPRomics Development

  9/28/2018

  Just this morning, KSQ Therapeutics disclosed that they’ve obtained an $80 million Series C financing that will be put towards the development of oncology drug candidates via CRISPRomics™, a drug discovery engine that creates insights specific to individual human genes on an industrial scale.

• BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors

  6/12/2018

  BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.

• KSQ Emerges With $76 Million and Will be Helmed by Former Genzyme CEO

  10/3/2017